ClinicalTrials.gg
TerminatedNCT05928845Updated Sep 29, 2026

Sternocleidomastoid Thickness in Sarcopenia

An observational study in Sarcopenia, sponsored by Namik Kemal University. Terminated at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Namik Kemal University · Observational

How we know

Why this study was terminated
Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
Updated Sep 29, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.

Enrollment
95th of 97
20 · median 100
Started
2025
with 24 others
Observational
97 of 131
30 open now
Registered
33rd of 131
by date

Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 95th largest by enrollment of the 97 observational ones that give a count, is one of 25 that started in 2025, is one of 97 observational ones, and was the 33rd registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Sarcopenia with a site in Turkey, or all of them as a file.
02

Study summary

In order to prevent sarcopenia in intensive care patients and to guide nutritional therapy, evaluation of muscle thickness with ultrasonography is a modern, simple and non-invasive procedure routinely performed by Anesthesiology and Reanimation specialists. Sarcopenia in intensive care patients has been demonstrated in many studies. It has been studied that routine examination of changes in rectus femoris muscle thickness by ultrasonography is a predictor of sarcopenia. However, the muscles in the neck region, such as the sternocleidomastoid muscle, which are easy to examine, have not been studied very well. There is no study in the literature with the sternocleidomastoid muscle. For this reason, we decided to examine the relationship of sternocleidomastoid muscle thickness with patient characteristics, treatments, feeding route and type, feeding time, length of stay in intensive care unit, as in routine measurements of rectus femoris muscle thickness by ultrasonography.

Read the detailed description

Sarcopenia is an important clinical condition, characterized by a decrease in muscle mass and function that increases with age, especially in elderly patients. Studies have shown that sarcopenic patients have higher morbidity and mortality rates than non-sarcopenic patients. Along with the increased risk of muscle wasting in intensive care patients, there is an increase in both hospital mortality rates and the frequency of post-hospital mobilization problems.

Intensive care patients are a group of patients who are very prone to protein-energy malnutrition, and this leads to complications such as nosocomial infection and multiple organ failure, leading to prolongation of the stay in the intensive care unit, as well as an increase in morbidity and mortality. Therefore, nutritional support is a routine requirement of intensive care treatment and has a vital role in the prevention and treatment of nutritional deficiencies in intensive care patients.

The first point that should be evaluated in terms of the follow-up of a patient on whom nutritional support is maintained is to know for what reason, when, and what kind of treatment is planned in terms of quality and quantity. This is a starting point for monitoring. Knowing the patient's clinical and laboratory values when nutritional therapy is initiated allows the evaluation of how these data have changed during follow-up. The purpose of assessment of nutritional status is to identify the type and degree of malnutrition in order to make a rational treatment approach. However, there is no test that is both sensitive and specific to determine malnutrition in intensive care patients.

03

Conditions studied

  • Sarcopenia

Browse trials for

Keywords

  • sarcopenia
  • intensive care
  • ultrasonography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who are expected to be followed up in the intensive care unit for at least 1 week in a tertiary university research and education hospital based 11 bed ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are expected to be followed up in the intensive care unit for at least 1 week
  • Patients over 18 years old

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • Head-neck, femur trauma patients
  • Those with a diagnosis of primary neuromuscular disease
  • Those who have a condition that prevents imaging in the body parts where ultrasonography is planned
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (actual)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Muscle thickness measurement

    Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography

    Diagnostic Test: Muscle thickness measurement

Interventions

  • Diagnostic testMuscle thickness measurement

    Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission

06

What researchers measure

Primary outcomes

  1. Muscle thickness

    Rectus femoris and Sternocleidomastoideus muscle thickness change when compared to the value measured at admission to the intensive care unit.

    Time frame: 1 week

Secondary outcomes

  1. Nutrition regime

    Nutrition regimes, calorie and protein intake during admission will be saved.

    Time frame: 1week

  2. Nutrition Scores

    NRS 2002, NUTRIC scores will be calculated in admission

    Time frame: Day 1

07

Study locations

1 site
  • Tekirdag Namik Kemal University
    Tekirdağ, Turkey (Türkiye)
08

References and documents

Publications

  • Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth. 2016 Oct;30(5):884-90. doi: 10.1007/s00540-016-2211-4. Epub 2016 Jul 4. PubMed 27376823 ↗
  • Rustani K, Kundisova L, Capecchi PL, Nante N, Bicchi M. Ultrasound measurement of rectus femoris muscle thickness as a quick screening test for sarcopenia assessment. Arch Gerontol Geriatr. 2019 Jul-Aug;83:151-154. doi: 10.1016/j.archger.2019.03.021. Epub 2019 Mar 27. PubMed 31029040 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2025 to primary completion in Sep 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Feb 2026 → Sep 2026 and completion Feb 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2023
First posted
Jul 3, 2023
StartActual
Sep 1, 2025
Primary completionActual
Sep 1, 2026was Feb 2026
CompletionActual
Sep 15, 2026was Feb 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
changed Sep 29, 2026
Primary completion
Feb 1, 2026→Sep 1, 2026 (actual)
Sep 29, 2026
Study completion
Feb 15, 2026→Sep 15, 2026 (actual)
Sep 29, 2026
Enrollment
80 (estimated)→20 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Terminated
    Why stopped Due to an overly detailed methodology and strict inclusion/exclusion criteria, patient recruitment was insufficient (poor accrual), leading to early termination of the study.
    Primary completion Feb 1, 2026→Sep 1, 2026 (now actual)
    Study completion Feb 15, 2026→Sep 15, 2026 (now actual)
    Enrollment 80 (estimated)→20 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05928845
Lead sponsor
Namik Kemal University
Responsible party
Onur Baran (Asst. Prof., Namik Kemal University) — Principal investigator
First posted
Jul 3, 2023
Start date
Sep 1, 2025
Primary completion
Sep 1, 2026
Completion
Sep 15, 2026
Last update
Sep 29, 2026

Study contacts

Onur Baran, Asst. Prof.
study director · Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey
Ayhan Şahin, Asst. Prof.
principal investigator · Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey
Cavidan Arar, Prof.
study chair · Department of Anesthesiology and Reanimation, Tekirdağ Namık Kemal University, Tekirdağ, Turkey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion